TroyGould advises Bone Biologics Corporation in its $5.1 million public offering
TroyGould represented Bone Biologics Corporation (NASDAQ: BBLG ) in a recent $5.1 million public offering under which the company issued 3,777,778 units at $1.35 per unit, with each unit consisting of (i) one share of common stock, (ii) one Series A warrant to purchase one share of common stock for $1.62 per share, (iii) one Series B warrant to purchase one share of common stock for $1.35 per share, and (iv) one Series C warrant to purchase one share of common stock at an exercise price equal to $2.16 per share. Bone Biologics is a medical device company focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBM. The company intends to use offering proceeds to fund clinical trials, maintain and extend its patent portfolio, retain contract research organizations, and for working capital purposes. WallachBeth Capital, LLC acted as sole book-running manager for the offering. The TroyGould team was led by David Ficksman. For more information, see this press release.
Celebrating 50 years of success as one of Southern California’s leading business law firms, TroyGould is recognized in the U.S. and abroad for its success in helping both U.S. and non-U.S entities and individuals achieve their business goals. The firm’s transactional and litigation clients range from emerging companies to middle-market and Fortune 500 companies across a diverse set of industries including life sciences, technology, entertainment/media, manufacturing, food and beverage, real estate, consumer products and health care. For more information, visit TroyGould.com.